Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T15:02:03.257Z.
Calculation as of: 2026-10-06T15:02:03.257Z.
Quote observation: 2026-10-06T15:00:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: de430a97f2ce1d56e5593aeaf7513a4829955f1ae9df1fe435740c279e59bff8
PEG RATIO
N/A
Hemab Therapeutics Holdings, Inc. Common Stock
Market Cap
$1.35B
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.46B
PEG Ratio
N/A
TTM Avg
1.94
3Y Avg
1.77
5Y Avg
2.38
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG) | $1.35B | N/A | N/A | N/A | N/A |
| Omeros Corporation (OMER)vs › | $1.35B | N/A | N/A | N/A | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.42B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.44B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | N/A | 1.94 | 1.77 | 2.38 |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.24B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
